Molbio Diagnostics Targets ₹940 Crore in IPO for Expansion and Stake Reduction

Molbio Diagnostics, a leading player in the molecular diagnostics field, is set to launch an initial public offering (IPO) aimed at raising ₹940 crore. This strategic move includes a fresh issue of shares worth ₹200 crore for capital expenditures and an offer for sale amounting to ₹740 crore. The IPO will see the promoter group's stake decrease from 46.6% to 43%.

Expanding Global Reach and Product Offerings

Established in 2000, Molbio Diagnostics has built a substantial presence with six manufacturing sites across India, serving over 90 countries. The company is renowned for its 'Truenat' platform, a portable diagnostic system that delivers quick and accurate test results in under an hour. With a focus on both infectious and non-communicable diseases, Molbio offers molecular testing solutions for over 30 diseases through 43 diagnostic assays.

The company's revenue is heavily supported by government and international aid agencies, which account for more than 80% of its income. Its tuberculosis diagnostic test kits, which contribute to 70% of the test kit sales, have been a significant driver of revenue growth.

Financial Performance and Market Position

Molbio's financial health has shown robust growth, with revenue from operations increasing by 31.5% annually to ₹1,445.7 crore between FY24 and FY26. The net profit saw a 40.2% annual growth, reaching ₹164.1 crore. During the same period, the company's EBITDA rose by 33.2% to ₹328.2 crore, with an improved EBITDA margin of 22.6% in FY26, up from 22% in FY24.

In FY26 alone, Molbio reported a 41.7% rise in revenue, a 27.9% increase in EBITDA, and an 18.4% growth in net profit compared to the previous year. Despite having no direct listed peers in India, Molbio's valuation demands a price-earnings (P/E) multiple of up to 57, aligning it with other notable companies in the healthcare diagnostics and medical device sectors.

Investor Considerations

Molbio’s IPO presents a potential opportunity for high-risk investors seeking long-term growth. The company's strong foothold in global markets and its innovative diagnostic solutions position it well for future expansion. However, the heavy reliance on a few key clients for over half of its revenue indicates a concentration risk that investors should consider.

With the upcoming IPO, Molbio aims to further bolster its capital foundation, allowing for enhanced operational capabilities and the ability to tap into emerging markets. As the company continues to innovate and expand its product offerings, it remains an attractive option for investors looking to invest in the rapidly growing diagnostics sector.